Literature DB >> 7892013

Pain in the Guillain-Barré syndrome: a clinical review.

Brian Pentland1, Stewart M Donald.   

Abstract

The Guillain-Barré syndrome, or acute inflammatory polyneuropathy, is often regarded as a predominantly motor neuropathy with few sensory features, which has a good prognosis in most cases. However, pain is a common symptom occurring in up to 72% of cases. The types of pain are protean including paraesthesiae, dysaesthesia, axial and radicular pain, meningism, myalgia, joint pain and visceral discomfort, etc., and patients may present in a variety of clinical settings such as intensive care units, acute medical wards or rehabilitation departments. These factors, combined with the fact that the condition is relatively uncommon, means that no controlled trial of pain management has been done and a range of treatments has been proposed. We review the various pains which may be associated with Guillain-Barré syndrome and discuss suggestions for their management.

Entities:  

Mesh:

Year:  1994        PMID: 7892013     DOI: 10.1016/0304-3959(94)90068-X

Source DB:  PubMed          Journal:  Pain        ISSN: 0304-3959            Impact factor:   6.961


  15 in total

1.  The boy who stopped walking….

Authors:  Mohamed Osman Eltahir Babiker
Journal:  Sudan J Paediatr       Date:  2015

Review 2.  Pharmacological treatment for pain in Guillain-Barré syndrome.

Authors:  Jia Liu; Lu-Ning Wang; Ewan D McNicol
Journal:  Cochrane Database Syst Rev       Date:  2015-04-09

3.  Focal lysolecithin-induced demyelination of peripheral afferents results in neuropathic pain behavior that is attenuated by cannabinoids.

Authors:  Victoria C J Wallace; David F Cottrell; Peter J Brophy; Susan M Fleetwood-Walker
Journal:  J Neurosci       Date:  2003-04-15       Impact factor: 6.167

4.  Dysautonomia and hyponatraemia as harbingers of Guillain-Barre syndrome.

Authors:  Preet Mukesh Shah; Vijay Waman Dhakre; Ramya Veerasuri; Anand Bhabhor
Journal:  BMJ Case Rep       Date:  2019-04-15

5.  Schwann cell LRP1 regulates remak bundle ultrastructure and axonal interactions to prevent neuropathic pain.

Authors:  Sumihisa Orita; Kenneth Henry; Elisabetta Mantuano; Kazuyo Yamauchi; Alice De Corato; Tetsuhiro Ishikawa; M Laura Feltri; Lawrence Wrabetz; Alban Gaultier; Melanie Pollack; Mark Ellisman; Kazuhisa Takahashi; Steven L Gonias; W Marie Campana
Journal:  J Neurosci       Date:  2013-03-27       Impact factor: 6.167

Review 6.  Proximal nerve lesions in early Guillain-Barré syndrome: implications for pathogenesis and disease classification.

Authors:  José Berciano; María J Sedano; Ana L Pelayo-Negro; Antonio García; Pedro Orizaola; Elena Gallardo; Miguel Lafarga; María T Berciano; Bart C Jacobs
Journal:  J Neurol       Date:  2016-06-17       Impact factor: 4.849

7.  Determination of pain and response to methylprednisolone in Guillain-Barré syndrome.

Authors:  Liselotte Ruts; Rinske van Koningsveld; Bart C Jacobs; Pieter A van Doorn
Journal:  J Neurol       Date:  2007-04-11       Impact factor: 4.849

8.  Neuropathic pain in animal models of nervous system autoimmune diseases.

Authors:  David H Tian; Chamini J Perera; Gila Moalem-Taylor
Journal:  Mediators Inflamm       Date:  2013-05-08       Impact factor: 4.711

Review 9.  Peripheral mechanisms of neuropathic pain - involvement of lysophosphatidic acid receptor-mediated demyelination.

Authors:  Hiroshi Ueda
Journal:  Mol Pain       Date:  2008-04-01       Impact factor: 3.395

10.  Phase IIB Randomized Trial on the Use of 4-Aminopyridine in Guillain-Barré Syndrome.

Authors:  Jay M Meythaler; Robert C Brunner; Jean Peduzzi
Journal:  Arch Rehabil Res Clin Transl       Date:  2021-04-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.